Tolvaptan phosphate sodium | vasopressin receptor 2 antagonist | CAS#942619-79-6

MedKoo Cat#: 124496 | Name: Tolvaptan phosphate sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tolvaptan is a selective, competitive vasopressin receptor 2 antagonist.

Chemical Structure

Tolvaptan phosphate sodium

CAS#942619-79-6

Theoretical Analysis

MedKoo Cat#: 124496

Name: Tolvaptan phosphate sodium

CAS#: 942619-79-6

Chemical Formula: C26H24ClN2Na2O6P

Exact Mass: 572.0900

Molecular Weight: 572.89

Elemental Analysis: C, 54.51; H, 4.22; Cl, 6.19; N, 4.89; Na, 8.03; O, 16.76; P, 5.41

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Tolvaptan phosphate sodium; Tolvaptan sodium phosphate; Y4P6WS9QVF; Tolvaptan sodium phosphate [JAN]; UNII-Y4P6WS9QVF

IUPAC/Chemical Name

sodium 7-chloro-1-(2-methyl-4-(2-methylbenzamido)benzoyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl phosphate

InChi Key

IHNKFKPPZJVMMZ-UHFFFAOYSA-L

InChi Code

InChI=1S/C26H26ClN2O6P.2Na/c1-16-6-3-4-7-20(16)25(30)28-19-10-11-21(17(2)14-19)26(31)29-13-5-8-24(35-36(32,33)34)22-15-18(27)9-12-23(22)29;;/h3-4,6-7,9-12,14-15,24H,5,8,13H2,1-2H3,(H,28,30)(H2,32,33,34);;/q;2*+1/p-2

SMILES Code

CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)OP(=O)([O-])[O-])C.[Na+].[Na+]

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 572.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sami SA, Moffett BS, Karlsten ML, Cabrera AG, Price JF, Dreyer WJ, Denfield SW, Jeewa A. Novel Use of Tolvaptan in a Pediatric Patient With Congestive Heart Failure Due to Duchenne Muscular Dystrophy and Congenital Adrenal Hyperplasia. J Pediatr Pharmacol Ther. 2015 Sep-Oct;20(5):393-6. doi: 10.5863/1551-6776-20.5.393. PubMed PMID: 26472954; PubMed Central PMCID: PMC4596126. 2: Vaduganathan M, Goldsmith SR, Senni M, Butler J, Gheorghiade M. Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial. Eur J Heart Fail. 2015 Oct 7. doi: 10.1002/ejhf.415. [Epub ahead of print] PubMed PMID: 26443242. 3: De Las Peñas R, Ponce S, Henao F, Camps Herrero C, Carcereny E, Escobar Álvarez Y, Rodríguez CA, Virizuela JA, López López R. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan. Support Care Cancer. 2015 Oct 2. [Epub ahead of print] PubMed PMID: 26431960. 4: Ogawa H, Ajioka M, Ishii H, Okumura T, Murase Y, Osanai H, Nakasima Y, Asano H, Sakai K, Murohara T. Long-term effects of tolvaptan in patients requiring recurrent hospitalization for heart failure. Nagoya J Med Sci. 2015 Aug;77(3):355-62. PubMed PMID: 26412881; PubMed Central PMCID: PMC4574322. 5: Nishi H, Toda K, Miyagawa S, Yoshikawa Y, Fukushima S, Kawamura M, Yoshioka D, Saito T, Ueno T, Kuratani T, Sawa Y. Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial. Surg Today. 2015 Sep 28. [Epub ahead of print] PubMed PMID: 26411431. 6: Blair HA, Keating GM. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease. Drugs. 2015 Oct;75(15):1797-806. doi: 10.1007/s40265-015-0475-x. PubMed PMID: 26407729. 7: Olin JL, Mitchell G, Cremisi H. Experience with Tolvaptan for Euvolemic and Hypervolemic Hyponatremia in the Acute Care Setting. Hosp Pharm. 2015 May;50(5):380-5. doi: 10.1310/hpj5005-380. PubMed PMID: 26405324; PubMed Central PMCID: PMC4567204. 8: Tzoulis P, Waung JA, Bagkeris E, Carr H, Khoo B, Cohen M, Bouloux PM. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion. Clin Endocrinol (Oxf). 2015 Sep 19. doi: 10.1111/cen.12943. [Epub ahead of print] PubMed PMID: 26385871. 9: Felker GM, Mentz RJ, Adams KF, Cole RT, Egnaczyk GF, Patel CB, Fiuzat M, Gregory D, Wedge P, O'Connor CM, Udelson JE, Konstam MA. Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials. Circ Heart Fail. 2015 Sep;8(5):997-1005. doi: 10.1161/CIRCHEARTFAILURE.115.002259. PubMed PMID: 26374918. 10: Kimura M, Nawata K, Kinoshita O, Hatano M, Imamura T, Kinugawa K, Ono M. Successful Treatment of Intractable Fluid Retention Using Tolvaptan After Treatment for Postoperative Mediastinitis in a Patient With a Left Ventricular Assist Device. Int Heart J. 2015 Sep 29;56(5):574-7. doi: 10.1536/ihj.14-412. Epub 2015 Sep 11. PubMed PMID: 26370363. 11: Kinugawa K, Inomata T, Sato N, Yasuda M, Shimakawa T, Bando K, Mizuguchi K. Errata: Effectiveness and Adverse Events of Tolvaptan in Octogenarians With Heart Failure. Int Heart J. 2015 Sep 29;56(5):581. doi: 10.1536/ihj.56-5_Errata1. Epub 2015 Sep 4. PubMed PMID: 26346521. 12: Xiong B, Huang Y, Tan J, Yao Y, Wang C, Qian J, Rong S, Deng S, Cao Y, Zou Y, Huang J. The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials. Heart Fail Rev. 2015 Nov;20(6):633-42. doi: 10.1007/s10741-015-9503-x. PubMed PMID: 26334632. 13: Harskamp LR, Gansevoort RT, Boertien WE, van Oeveren W, Engels GE, van Goor H, Meijer E. Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan. Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1749-56. doi: 10.2215/CJN.09941014. Epub 2015 Jul 31. PubMed PMID: 26231191. 14: Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, Zimmer CA. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database. Drug Saf. 2015 Nov;38(11):1103-13. doi: 10.1007/s40264-015-0327-3. PubMed PMID: 26188764; PubMed Central PMCID: PMC4608984. 15: Tanaka A, Katsuno T, Ozaki T, Sakata F, Kato N, Suzuki Y, Kosugi T, Kato S, Tsuboi N, Sato W, Yasuda Y, Mizuno M, Ito Y, Matsuo S, Maruyama S. The efficacy of tolvaptan as a diuretic for chronic kidney disease patients. Acta Cardiol. 2015 Apr;70(2):217-23. PubMed PMID: 26148383. 16: Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol. 2015 Jun 28;7(12):1685-93. doi: 10.4254/wjh.v7.i12.1685. PubMed PMID: 26140088; PubMed Central PMCID: PMC4483550. 17: Horie S. Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease? Kidney Int. 2015 Jul;88(1):14-6. doi: 10.1038/ki.2015.143. PubMed PMID: 26126090. 18: Kogiso T, Tokushige K, Hashimoto E, Ikarashi Y, Kodama K, Taniai M, Torii N, Shiratori K. Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis. Hepatol Res. 2015 Jun 29. doi: 10.1111/hepr.12547. [Epub ahead of print] PubMed PMID: 26123753. 19: Okabe T, Yakushiji T, Igawa W, Ono M, Kido T, Ebara S, Yamashita K, Yamamoto MH, Saito S, Hoshimoto K, Amemiya K, Isomura N, Araki H, Ochiai M. The Efficacy of Tolvaptan in Congestive Heart Failure Patients with and Without Hypoalbuminemia: A Pilot Study. Cardiovasc Ther. 2015 Oct;33(5):275-81. doi: 10.1111/1755-5922.12142. PubMed PMID: 26122275. 20: Toda H, Nakamura K, Nakahama M, Wada T, Watanabe A, Hashimoto K, Terasaka R, Tokioka K, Nishii N, Miyoshi T, Kohno K, Kawai Y, Miyaji K, Koide Y, Tachibana M, Yoshioka R, Ito H; Tolvaptan Registry Investigators. Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size. J Cardiol. 2015 Jun 10. pii: S0914-5087(15)00153-7. doi: 10.1016/j.jjcc.2015.04.017. [Epub ahead of print] PubMed PMID: 26072263.